Page 33 - Nsclc News Today

Selpercatinib significantly improved progression-free survival vs platinum-based chemotherapy plus pemetrexed and pembrolizumab in patients with advanced or metastatic non–small cell lung cancer harboring RET fusions.

Tina Cascone, MD, Ben Levy, MD, and Sandip Patel, MD, offer insights into the treatment approach in patients with unresectable early-stage NSCLC who are unsuitable for consolidation durvalumab or who progress on consolidation durvalumab.

Wildfire smoke is associated with worse survival for individuals with non–small cell lung cancer (NSCLC) who are recovering from surgical resection treatment.

Expert oncologists Laurent Greiller, MD, and Christian Grohé, MD, make introductions and review the current paradigm for small cell lung cancer diagnosis and classification.

Analysis suggests tumor histology plays an important role in determining the best first-line approach for patients who have non–small cell lung cancer (NSCLC).

A panel of expert oncologists present the case of a 78-year-old woman who is treated with lurbinectedin following disease progress on first-line carboplatin, etoposide, and atezolizumab.

Researchers seeking answers regarding the most beneficial duration of immune checkpoint inhibitor–based therapy for non–small cell lung cancer (NSCLC) found no significant impact of indefinite-duration treatment on patient survival.

Deborah B. Doroshow, MD, PhD, discusses the efficacy and toxicity profiles of pralsetinib and selpercatinib and how they influence treatment selection for patients with RET fusion–positive non–small cell lung cancer, and provides insight on several areas of ongoing or potential research in lung cancer.

Sandip Patel, MD, shares his expert perspectives on novel combination consolidation immunotherapy regimens that are under evaluation in unresectable early-stage NSCLC.

Sugemalimab plus chemotherapy demonstrated statistically significant and clinically meaningful improvements in progression-free survival and overall survival vs placebo plus chemotherapy for the first-line treatment of patients with stage IV non–small cell lung cancer irrespective of PD-L1 expression level and tumor pathological type.